SEC Form 3 · accession 0001615774-17-004487
Inspyr Therapeutics, Inc. · NSPX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Robison Montgomery
Director
Period of report
Jul 31, 2017
Accepted (ET)
Aug 15, 2017 · 6:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001421204
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 236,163 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Purchase OptionF2 | $0.348 | holding | — | — | — | Jul 31, 2017 | Jul 31, 2022 | Common Stock | 2,500 | — | D |
Explanation of responses
- F1Represents common shares received pursuant to a share exchange agreement with Lewis & Clark Pharmaceuticals, and subject to lock-up for 18 months from the acquisition date. The shares are held in joint tenancy.
- F2Represents compensatory stock option grant for director services upon joining the Board of Directors. The options vest fully on August 1, 2018, subject to Mr. Montgomery continuously providing services to the Company during such vesting period.